California State Teachers Retirement System Has $7.91 Million Stake in Vaxcyte, Inc. $PCVX

Posted by George Bondi on Aug 5th, 2026

California State Teachers Retirement System raised its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX – Free Report) by 22.8% in the 1st quarter, Holdings Channel reports. The firm owned 136,100 shares of the company’s stock after purchasing an additional 25,238 shares during the quarter. California State Teachers Retirement System’s holdings in Vaxcyte were worth $7,909,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. EverSource Wealth Advisors LLC boosted its stake in shares of Vaxcyte by 33.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock valued at $34,000 after purchasing an additional 184 shares during the last quarter. Meeder Advisory Services Inc. raised its stake in Vaxcyte by 2.9% during the first quarter. Meeder Advisory Services Inc. now owns 8,335 shares of the company’s stock worth $484,000 after buying an additional 231 shares during the last quarter. CWM LLC lifted its holdings in Vaxcyte by 9.0% in the fourth quarter. CWM LLC now owns 2,840 shares of the company’s stock valued at $131,000 after buying an additional 234 shares during the period. Principal Financial Group Inc. lifted its holdings in Vaxcyte by 7.0% in the first quarter. Principal Financial Group Inc. now owns 5,275 shares of the company’s stock valued at $307,000 after buying an additional 343 shares during the period. Finally, Smartleaf Asset Management LLC boosted its position in Vaxcyte by 156.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 597 shares of the company’s stock valued at $27,000 after acquiring an additional 364 shares during the last quarter. Institutional investors and hedge funds own 96.78% of the company’s stock.

Insider Buying and Selling

In other news, COO Jim Wassil sold 2,250 shares of the business’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $49.52, for a total transaction of $111,420.00. Following the completion of the sale, the chief operating officer directly owned 158,494 shares of the company’s stock, valued at $7,848,622.88. The trade was a 1.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Grant Pickering sold 22,461 shares of the firm’s stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $52.50, for a total transaction of $1,179,202.50. Following the completion of the transaction, the chief executive officer directly owned 474,703 shares in the company, valued at approximately $24,921,907.50. The trade was a 4.52% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 91,396 shares of company stock worth $4,975,725 in the last ninety days. Corporate insiders own 3.30% of the company’s stock.

Vaxcyte Price Performance

Shares of Vaxcyte stock opened at $54.69 on Wednesday. The business has a 50-day simple moving average of $53.47 and a 200 day simple moving average of $55.05. Vaxcyte, Inc. has a one year low of $29.08 and a one year high of $65.00. The firm has a market capitalization of $7.90 billion, a price-to-earnings ratio of -7.95 and a beta of 1.23.

Vaxcyte (NASDAQ:PCVX – Get Free Report) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($2.30) EPS for the quarter, missing analysts’ consensus estimates of ($1.74) by ($0.56). During the same quarter in the previous year, the business earned ($1.04) earnings per share. On average, sell-side analysts expect that Vaxcyte, Inc. will post -7.91 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on PCVX. Zacks Research downgraded Vaxcyte from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 14th. Wall Street Zen lowered Vaxcyte from a “sell” rating to a “strong sell” rating in a research report on Tuesday, April 28th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a research note on Monday, July 6th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $86.00.

Read Our Latest Research Report on Vaxcyte

Vaxcyte Profile

(Free Report)

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.